Angiogenic Switch in Patients With Colorectal Cancer (ANGIOSWITCH)

Grupo Hospital de Madrid

Status and phase

Unknown

Phase 2

Conditions

Colorectal Cancer

Treatments

Drug: Xelox or Xeliri Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT02075086

ANGIOSWITCH2011

Details and patient eligibility

About

A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .

Enrollment

100 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of stage IV colorectal adenocarcinoma.
Age ≥ 18 years .
Measurable disease by RECIST criteria.
Life expectancy ≥ 6 months.
Candidate to receive treatment with first-line chemotherapy.
Availability of tumor tissue.

Exclusion criteria

Patients who have received prior treatment with first-line chemotherapy for metastatic disease.
Patients in whom there is contraindication to the administration of either drug used in the study: capecitabine, irinotecan, oxaliplatin or Bev.
Patients receiving anticoagulant oral treatment.
Patient with diagnosis of other malignancies within 5 years prior to diagnosis except basal cell carcinoma or cervical carcinoma · in situ. · The inclusion of patients with malignant disease diagnosed more than 5 years ago without recurrence in the previous 3 years will be analyzed individually
Patients with bone disease as the only manifestation of the disease.